SCHEMBL3640892

SCHEMBL3640892

CCS(=O)(=O)Nc1ccc(Cl)c(NC2=NC(=O)/C(=C/c3ccc4ncccc4c3)S2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK3 O43781 4/20 0.43
PIK3CD O00329 1/20 0.41
PIM1 P11309 1/20 0.41
CSNK2A2 P19784 1/20 0.41
PIK3CA P42336 1/20 0.41
PIK3CG P48736 1/20 0.41
CLK1 P49759 1/20 0.41
CLK3 P49761 1/20 0.41
CSNK2B P67870 1/20 0.41
CSNK2A1 P68400 1/20 0.41
DYRK1A Q13627 1/20 0.41
HASPIN Q8TF76 1/20 0.41
DYRK2 Q92630 1/20 0.41
MYLK2 Q9H1R3 1/20 0.41
CLK4 Q9HAZ1 1/20 0.41
STK17A Q9UEE5 1/20 0.41
DYRK1B Q9Y463 1/20 0.41
BRAF P15056 1/20 0.38
CDK1 P06493 4/20 0.37
PRKCD Q05655 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3640896 1.00 DYRK3 (0.43) DYRK3PIK3CDPIM1CSNK2A2PIK3CA
SCHEMBL2992959 0.94 BRAF (0.45) DYRK3PIK3CDPIM1CSNK2A2PIK3CA
SCHEMBL2992958 0.94 BRAF (0.45) DYRK3PIK3CDPIM1CSNK2A2PIK3CA
SCHEMBL4953292 0.92 DYRK3 (0.41) DYRK3PIK3CDPIM1CSNK2A2PIK3CA
SCHEMBL2990580 0.92 DYRK3 (0.44) DYRK3PIK3CDPIM1CSNK2A2PIK3CA
SCHEMBL2990583 0.92 DYRK3 (0.44) DYRK3PIK3CDPIM1CSNK2A2PIK3CA
SCHEMBL2992776 0.90 DYRK3 (0.42) DYRK3PIK3CDPIM1CSNK2A2PIK3CA
SCHEMBL2992779 0.90 DYRK3 (0.42) DYRK3PIK3CDPIM1CSNK2A2PIK3CA
SCHEMBL2997669 0.90 DYRK3 (0.43) DYRK3PIK3CDPIM1CSNK2A2PIK3CA
SCHEMBL2997668 0.90 DYRK3 (0.43) DYRK3PIK3CDPIM1CSNK2A2PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-08-13 US claimed
EP-1885362-A2 NOVEL CHEMICAL COMPOUNDS Smithkline Beecham Corporation (US) 2008-02-13 EP claimed
WO-2006127458-A2 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-30 WO claimed
EP-2164494-A1 METHODS OF TREATMENT GlaxoSmithKline LLC (US) 2010-03-24 EP disclosed
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS SMITHKLINE BEECHAM CORPORATION 2009-08-13 US disclosed
WO-2008150837-A1 METHODS OF TREATMENT SMITHKLINE BEECHAM CORPORATION (US) 2008-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090203692-A1 NOVEL CHEMICAL COMPOUNDS HIPK3, HIPK1, HIPK4 DYRK3 1471/4885PIK3CD 2485/4885PIM1 2800/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.